USA flag logo/image

An Official Website of the United States Government

Modification of Intervertebral Disk Fatigue Resistance

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
54296
Program Year/Program:
2001 / STTR
Agency Tracking Number:
1R41AR047470-01A1
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
AMPAC BIOTECHNOLOGY
25665 FROST LN STEVENSON RANCH, CA 91381 LOS ANGELES, CA 91381
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2001
Title: Modification of Intervertebral Disk Fatigue Resistance
Agency: HHS
Contract: PHS2001-2
Award Amount: $98,894.00
 

Abstract:

DESCRIPTION (Provided by Applicant): An investigation is proposed exploring the use of biochemical reagents to improve fatigue resistance of intervertebral disc tissue. While not well quantified, the capacity of spinal tissue to withstand repetitive loading is a critically important factor in the progression of spinal osteoarthritis. Current treatments for spinal instability and low-back pain, including spinal fusion, are generally ineffective in slowing the progression of degeneration. Biochemical alterations in the structure of the annular matrix could have significant effects on the disc's ability to withstand repetitive mechanical loading. We intend to study the effectiveness of certain reagents in maintaining the mechanical properties of disc tissues subjected to non-traumatic fatigue loading. Preliminary experiments in our laboratory using novel destructive and non-destructive mechanical testing techniques have shown degradation of elastic-plastic and viscoelastic material properties of disc tissues subjected to non-traumatic cyclic loads. If these reagents are effective in improving fatigue resistance of intervertebral discs, a new, minimally invasive treatment may be developed which will be able to improve the degenerated disc's ability to withstand repetitive physiological loads. This type of treatment has the potential of improving or even replacing numerous surgical interventions directed at the ubiquitous problems of low back pain and instability. PROPOSED COMMERCIAL APPLICATION: Back pain and disability associated with spinal degeneration and instability is without question one of the costliest health problems in western civilization (in the range of $20 billion U.S. annually- low-back-pain alone). The commercial potential of a minimally invasive treatment (perhaps a series of injections) capable of arresting degradation and stabilizing intervertebral discs would be staggering. In addition, such treatment could be used as an additional preventative procedure in fusion surgery, where accelerated degeneration commonly occurs at the level adjacent to the fusion.

Principal Investigator:

Thomas P. Hedman
3234423337
HEDMAN@HSC.USC.EDU

Business Contact:

Hedman, sow-foong, l
6612558696
SOWFOONG@ALUM.MIT.EDU
Small Business Information at Submission:

AMPAC BIOTECHNOLOGY
25665 FROST LN STEVENSON RANCH, CA 91381 LOS ANGELES, CA 91381

EIN/Tax ID: 954787607
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
UNIVERSITY OF SOUTHERN CALIFORNIA
UNIVERSITY OF SOUTHERN CALIFORNIA
LOS ANGELES, CA 98507
RI Type: Nonprofit college or university